Detalhe da pesquisa
1.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Nature
; 623(7989): 1053-1061, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37844613
2.
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.
Nature
; 559(7714): 363-369, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29950727
3.
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer.
Lab Invest
; 103(11): 100245, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37652207
4.
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 162-174, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806540
5.
Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).
Int J Cancer
; 143(10): 2584-2591, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30006930
6.
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
BJU Int
; 120(5B): E30-E44, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27539393
7.
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Eur J Cancer
; 205: 114103, 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729054
8.
Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer.
Mol Cancer Ther
; 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38412481
9.
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer.
Cancer Cell
; 41(3): 602-619.e11, 2023 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868226
10.
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells.
Nat Cancer
; 4(8): 1102-1121, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37460872
11.
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Eur Urol
; 83(3): 224-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36114082
12.
Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.
Clin Cancer Res
; 28(14): 3104-3115, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552383
13.
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.
Eur Urol Oncol
; 5(6): 659-667, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35491356
14.
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
J Immunother Cancer
; 10(6)2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717027
15.
HER3 expression and MEK activation in non-small-cell lung carcinoma.
Lung Cancer Manag
; 10(2): LMT48, 2021 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34084213
16.
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.
Cancer Treat Res Commun
; 27: 100309, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33549985
17.
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Cancer Discov
; 11(11): 2812-2827, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34045297
18.
CD38 in Advanced Prostate Cancers.
Eur Urol
; 79(6): 736-746, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33678520
19.
Characterizing CDK12-Mutated Prostate Cancers.
Clin Cancer Res
; 27(2): 566-574, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988971
20.
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
Cancer Res
; 81(4): 1087-1100, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822745